【高端访谈】不只是“BD之王” 和铂医药“新基建”模式打造中国Biotech全球化“新样本”

新华财经
23 Jul

新华财经上海7月23日电(记者杜康)2025年上半年,中国Biotech迎来了一轮前所未有的结构性重估行情。港股创新药板块成为市场最大亮点,截至6月末,恒生港股通创新药指数年内累计涨幅超60%。这背后,是中国创新药出海不断拿下大单。从跟跑,到并跑,再到部分领域的领跑,中国创新药经历了蓬勃发展的十年。2025年上半年,中国创新药领域达成超50笔全球合作,总额达484.48亿美元。和铂医药在中国创新药...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10